— Jeremy Schafer, Pharm.D., senior vice president of specialty solutions at Precision for Value, tells Specialty Pharmacy News about new oncology immunotherapies such as Yervoy and Keytruda.
Monday, June 12, 2017
Quote of the Day
With
immunotherapy product combinations that "well exceed $200,000 per
year," the payer perspective is "where does it end, or does it keep
going, and how do I provide access" to members?
— Jeremy Schafer, Pharm.D., senior vice president of specialty solutions at Precision for Value, tells Specialty Pharmacy News about new oncology immunotherapies such as Yervoy and Keytruda.
— Jeremy Schafer, Pharm.D., senior vice president of specialty solutions at Precision for Value, tells Specialty Pharmacy News about new oncology immunotherapies such as Yervoy and Keytruda.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment